The 120th AUA Annual Meeting, held in Las Vegas, ran from April 26 to April 29. The event gathered urologists and healthcare experts from around the world for an unrivaled experience featuring new guideline revelations, groundbreaking research, and discussions on the latest advancements in urologic medicine.
The following news rundown represents just a sampling of the exciting developments discussed at AUA2025.
SOUL Trial Reveals Clear Patient Preference: Skip the Stent After Ureteroscopy
Description: Findings from the Stent Omission after Ureteroscopy and Lithotripsy (SOUL) trial revealed patients may benefit from the omission of a ureteral stent following a ureteroscopy. Previously, it was reported that stent placement notably increased the occurrence of unplanned emergency department visits after surgery. The study will ultimately help iron out conflicting reports regarding stenting practices from prior clinical trials.
Renal Stone Care Reimagined
Description: A trio of trial results were shared on April 27 regarding the management of renal stones. The results of the largest stone intervention trial to date, the PUSH (prevention of urinary stones with hydration) trial, revealed that increased hydration resulted in no change in symptomatic recurrence of urinary stone disease. The second trial found that both high-powered Holmium:YAG and high-powered thulium fiber lasers are effective and safe options for removal of renal stones. The third trial discussed the collected data that patients prefer to have no stent put in after uncomplicated ureteroscopy for renal stones.
Novel Interventions Show Promise for Bladder Cancer
Description: New treatments for bladder cancer were featured during a presentation at the meeting. Crestostimogene grenadenorepvec, a highly immunogenic adenovirus, demonstrated a high response rate in patients previously unresponsive to BCG therapy, with nearly 85% of patients avoiding cystectomy. TAR-200, a device managing sustained-release gemcitabine to the bladder, showed just over 82% complete response rate in patients who were previously unresponsive to BCG therapy.
Suction: A Game-changes in Endourology
Description: Suction through the ureter may be the new standard of care, as it replaces percutaneous nephrolithotomy (PCNL). New aspiration devices allow suction through the lumen via the ureter, as opposed to PCNL requiring surgical incision. Thanks to these innovative tools, virtually all fragments and stone dust can be removed and patients usually can return home the same day.
Check Out Some of Our AUA Guidelines Quizzes:
Microhematuri
Advanced Prostate Cancer
Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia
Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation
What Can AI Do For You?
Description: Urologists are quickly turning to AI tools to automate documentation, save time, and improve patient outcomes. Such tools can save countless hours extracting and analyzing patient history and notes. This automation allows more time with the patients, with physicians simply needing to conversationally confirm the generated information.
Bladder Cancer Clinical Trials Hold Promise for Improving Patient Outcomes
Description: The CUT-less Randomized Trial is an effort to lessen the chance of a second transurethral resection of bladder tumor. Re-TURBT, the current standard of care, is being compared to the preoperative staging accuracy of VI-RADS and the intraoperative enhanced ability of PDD. Other clinical trials are investigating new intravesical drug-releasing systems and test the efficacy of a new urine tumor DNA biomarker test.
For a complete look at all the news to come out of the AUA 2025 Conference, visit the AUA official website.
Sign up for alerts to stay informed on the latest published guidelines and more conference recaps.
Copyright © 2025 Guideline Central, all rights reserved.